TY - JOUR
T1 - Immune-Related Adverse Events in Patients with Lung Cancer
AU - Sacchi de Camargo Correia, Guilherme
AU - Pai, Tanmayi
AU - Li, Shenduo
AU - Connor, Dana
AU - Zhao, Yujie
AU - Lou, Yanyan
AU - Manochakian, Rami
N1 - Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2023/11
Y1 - 2023/11
N2 - Purpose of Review: Immune checkpoint inhibitors (ICI) have been widely adopted for the treatment of lung cancer since receiving first U.S Food and Drug Administration (FDA) approval in 2015. However, along with their use, the occurrence of immune-related adverse events (irAEs) has presented a challenge for both patients and oncology providers. In this manuscript, we reviewed the clinical trials that led to the approval of ICI by the FDA for the treatment of lung cancer between 2015 and 2023 to establish the frequency of irAEs in this patient population. Among the adverse events associated with ICI, we focused on the most common and relevant ones, including hypothyroidism, pneumonitis, diarrhea/colitis, skin rash, and hepatitis. Recent Findings: We thoroughly examined the available literature, including society guidelines concerning these complications, to discuss various aspects such as their pathophysiology, epidemiology, diagnostic process, grading system, and clinical management. Additionally, we explored the association between irAEs and disease response. Summary: The management of irAEs is a crucial aspect of oncologic care, particularly due to their potential to cause severe and life-threatening clinical manifestations. We present each pertinent aspect in a concise and organized manner to provide guidance and assistance to oncology providers managing these patients in both outpatient and inpatient settings.
AB - Purpose of Review: Immune checkpoint inhibitors (ICI) have been widely adopted for the treatment of lung cancer since receiving first U.S Food and Drug Administration (FDA) approval in 2015. However, along with their use, the occurrence of immune-related adverse events (irAEs) has presented a challenge for both patients and oncology providers. In this manuscript, we reviewed the clinical trials that led to the approval of ICI by the FDA for the treatment of lung cancer between 2015 and 2023 to establish the frequency of irAEs in this patient population. Among the adverse events associated with ICI, we focused on the most common and relevant ones, including hypothyroidism, pneumonitis, diarrhea/colitis, skin rash, and hepatitis. Recent Findings: We thoroughly examined the available literature, including society guidelines concerning these complications, to discuss various aspects such as their pathophysiology, epidemiology, diagnostic process, grading system, and clinical management. Additionally, we explored the association between irAEs and disease response. Summary: The management of irAEs is a crucial aspect of oncologic care, particularly due to their potential to cause severe and life-threatening clinical manifestations. We present each pertinent aspect in a concise and organized manner to provide guidance and assistance to oncology providers managing these patients in both outpatient and inpatient settings.
KW - Immune checkpoint inhibitors
KW - Immune-related adverse events
KW - Immunotherapy
KW - Lung cancer
UR - http://www.scopus.com/inward/record.url?scp=85173095314&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85173095314&partnerID=8YFLogxK
U2 - 10.1007/s11912-023-01462-w
DO - 10.1007/s11912-023-01462-w
M3 - Review article
C2 - 37782426
AN - SCOPUS:85173095314
SN - 1523-3790
VL - 25
SP - 1259
EP - 1275
JO - Current oncology reports
JF - Current oncology reports
IS - 11
ER -